News

ANI Pharmaceuticals Achieves Remarkable Growth in Revenue for 2024

ANI Pharmaceuticals Achieves Remarkable Growth in Revenue for 2024

ANI Pharmaceuticals Reports Impressive Year-End Results

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has recently shared a remarkable fiscal report announcing a record fourth quarter and an exceptional overall performance for the year. The company achieved unprecedented quarterly net revenues of $190.6 million, showing a significant year-over-year growth of 44.8%. This surge in revenue underscores the company's successful operational strategies and growing market presence.

Record Sales and EBITDA Highlights

Among the highlights, ANI's Rare Disease segment generated quarterly net revenues of $87.0 million. Within this segment, Purified Cortrophin Gel achieved record net revenues of $59.4 million, representing a 42.3% increase compared to the previous year. Additionally, the sales from ILUVIEN and YUTIQ amounted to $27.6 million, marking a strong debut in the market post-acquisition of Alimera Sciences.

Strong Operational Growth

The company delivered impressive adjusted non-GAAP EBITDA of $50 million, a growth of 65.7% year-over-year. Despite a reported diluted GAAP loss per share of $(0.55), ANI's adjusted non-GAAP diluted earnings per share reached $1.63, indicating a strong underlying operational performance.

Looking Ahead: Increased 2025 Guidance

Nikhil Lalwani, President and CEO of ANI, expressed excitement over the results and the company’s growth trajectory, stating, "We’re thrilled to report another year of strong execution for ANI, capped by our record fourth quarter results, with total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS all finishing above our previously announced guidance for the full year." In light of the growth momentum, ANI has revised its guidance for 2025, expecting net revenues to fall between $756 million and $776 million and adjusted non-GAAP EBITDA to be between $190 million and $200 million.

Innovative Product Portfolio

ANI Pharmaceuticals continues to strengthen its Rare Disease portfolio moving into 2025, with expectations that Rare Disease net revenues will comprise approximately 48% to 49% of total company revenues. Specifically, the company anticipates Purified Cortrophin Gel net revenues to range from $265 million to $274 million. The pipeline of innovative products, including ILUVIEN and YUTIQ, is anticipated to contribute significantly to the company’s growth in the upcoming years.

Focus on Supply Chain Security

The company is actively working to enhance supply security for its ILUVIEN and YUTIQ franchises. Recently, ANI has submitted a prior approval supplement (PAS) to the FDA to expand the ILUVIEN label, aiming to cover chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). With the expectation of FDA approval in the near future, ANI plans to aggressively market ILUVIEN for both new indications across different platforms, capitalizing on its diverse application potential.

Business Highlights and Continued Growth

In its Generics segment, ANI experienced a solid revenue growth of 9.4%, reaching $78.6 million during the quarter. The company attributed this performance to strong research and development capabilities, complemented by effective operational excellence leveraging its U.S.-based manufacturing. The launch of five new products during the last quarter and a total of 17 for the entire year exemplifies ANI's commitment to expanding its product offering effectively.

Financial Liquidity Status

As of the end of the fiscal year, ANI reported having $144.9 million in unrestricted cash and cash equivalents, alongside significant net accounts receivable of $221.7 million. The principal value of outstanding debt stood at $639.2 million. This strong liquidity position provides ANI with the financial flexibility necessary for continued investment in product development and market expansion.

Conclusion

With a robust operational strategy and a commitment to investing in healthcare innovation, ANI Pharmaceuticals is well-positioned for growth in the upcoming fiscal year. As the company aims to achieve its ambitious revenue targets while enhancing its product portfolio, stakeholders can look forward to an exciting horizon for ANI Pharmaceuticals.

Frequently Asked Questions

What were ANI Pharmaceuticals' total net revenues for 2024?

ANI Pharmaceuticals achieved total net revenues of $190.6 million for the fourth quarter of 2024.

How much did the company generate from the Purified Cortrophin Gel?

Purified Cortrophin Gel generated net revenues of $59.4 million in the fourth quarter of 2024, representing a 42.3% increase year-over-year.

What is the expected growth of ANI’s Rare Disease segment in 2025?

The Rare Disease segment's net revenues are expected to represent 48% to 49% of the total company net revenues in 2025.

Did ANI Pharmaceuticals raise their guidance for 2025?

Yes, ANI Pharmaceuticals raised its revenue guidance for 2025, now expecting net revenues between $756 million and $776 million.

What are ANI's anticipated projected earnings per share for 2025?

ANI has announced adjusted non-GAAP diluted earnings per share guidance of $6.12 to $6.49 for 2025.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 111

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 78

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 170

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 103

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 55

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 161

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 139

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 89

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Quantum X and Everest Cloud Partner in South Asia Push

Updated Category News Views 61

An Unlikely Alliance for Cutting-Edge Tech You gotta admit, the fusion of a U.S.-based tech outfit with a Nepalese cloud provider wasn't the market move anyone saw coming. But here we are—Quantum X is hitching its quantum computing dreams to Everest Cloud's solid local foothold across six South Asian markets. We're talking Nepal, India, Bangladesh, Bhutan, Sri Lanka,...

Continue Reading
Salvation Army’s Angel Tree: 2026 Holiday Cheer Drive

Updated Category News Views 120

Kickstarting Holiday Generosity: The Angel Tree Program Man, there's something heartwarming about a Christmas that shines bright for everyone. The Salvation Army's Angel Tree program is back for another season, rolling up with a mission to spark joy across the country. For over 45 years now, this initiative's been the answer to many Christmas wish lists, especially for...

Continue Reading

Top 5 Most Recently Viewed Articles

Gap Inc. Sees Minor Sales Growth Amid Market Challenges

Updated Category News Views 254

Gap Inc. Experiences Modest Growth Gap Inc. demonstrated resilience in a challenging market, achieving a 1% increase in net sales compared to the previous year. The comparable sales rose by 3%, reflecting the brand's enhancement strategies. Brand Performance Highlight Each of Gap Inc.'s four major brands—Old Navy, Gap, Banana Republic, and Athleta—gained market share,...

Continue Reading
Innovative Lock Design Enhances Security for Commercial Trailers

Updated Category News Views 761

The SMART LOC: A Game-Changer for Trucking Security In a world where cargo theft is a persistent challenge, the development of an innovative solution is essential. Enter the SMART LOC, a new locking mechanism designed specifically for commercial trailers. This invention aims to significantly enhance security for trucking professionals, ultimately providing much-needed...

Continue Reading
GXO Logistics Prepares for First Quarter Earnings Call Soon

Updated Category News Views 198

GXO Logistics Set for First Quarter Earnings Presentation GXO Logistics, Inc. (NYSE: GXO) is preparing for its first quarter earnings conference call, which is scheduled for May 8, 2025, at 8:30 a.m. Eastern Time. During this call, the company will share its financial results and key insights into its business performance. Interested participants are encouraged to join in...

Continue Reading
Legal Action Against Everus Construction Group for Investors

Updated Category News Views 132

Overview of Legal Proceedings Against Everus Construction Group Everus Construction Group, Inc. (NYSE: ECG) is currently facing significant legal challenges as a result of alleged securities law violations. The situation has prompted attention from shareholders and investors alike. The Gross Law Firm has taken the initiative to notify shareholders regarding this serious...

Continue Reading
Nxera Pharma and Cancer Research UK Collaborate to Combat Cancer

Updated Category News Views 121

Nxera Pharma Joins Forces with Cancer Research UK for Innovative Trials HTL0039732, a promising oral EP4 antagonist developed by Nxera, shows potential in tackling various types of cancer, especially when paired with leading immunotherapies. Currently, this drug is making progress through its Phase 1/2a clinical trials, highlighting its potential effectiveness across a...

Continue Reading